about
Suppression of breast tumor growth and metastasis by an engineered transcription factorEpigenome engineering in cancer: fairytale or a realistic path to the clinic?Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factorsThe recognition of a noncanonical RNA base pair by a zinc finger protein.Scanning the human genome with combinatorial transcription factor libraries.Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation.Genetic reprogramming of tumor cells by zinc finger transcription factorsModulation of drug resistance by artificial transcription factors.Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation.Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small moleculesReprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs)Designing transcription factor architectures for drug discovery.Gene expression in breastmilk cells is associated with maternal and infant characteristics.The CRISPR road: from bench to bedside on an RNA-guided path.Epigenetic reprogramming of cancer cells via targeted DNA methylation.Targeted silencing of the oncogenic transcription factor SOX2 in breast cancerStable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer.Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells.Breastmilk is a novel source of stem cells with multilineage differentiation potential.Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA.Long live the stem cell: the use of stem cells isolated from post mortem tissues for translational strategies.Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide.Remodeling genomes with artificial transcription factors (ATFs).Hallmarks of cancer: The CRISPR generation.Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells.Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing.Non-viral Methodology for Efficient Co-transfection.Atomistic molecular dynamics simulations of bioactive engrailed 1 interference peptides (EN1-iPeps).Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer CellsFrequent lack of repressive capacity of promoter DNA methylation identified through genome-wide epigenomic manipulationPolI-driven integrative expression vectors for yeastRe-activation of a dormant tumor suppressor gene maspin by designed transcription factorsTumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymersTumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
P50
Q21135222-C2C86A08-5ACA-4A23-BAC8-E750062BCB8DQ26861350-8DBB8654-9ACB-425F-B88B-A9372E4E5938Q28267768-B6A8526B-33CE-41E0-AB95-CD5A43FE3B70Q30743216-27778DED-A80B-4E4D-9DC2-3DFB4D729B2DQ30887293-D3D232F0-2913-44F3-BF71-C9E2EFF02DF3Q33204106-C6CBDDC0-A17A-464E-BF24-3194F62CD8E5Q33221141-37C67064-8985-4417-AC17-4BD5AE3D562FQ33322421-E1B19D29-A9D0-480A-A4E6-65903747B1B0Q34249565-40F2944A-53AC-47BD-A64A-A49ED5FCC599Q34285190-8344B04F-AF31-42D5-BF88-12008278F2E0Q34476349-1F3AB1B0-19D5-4EDF-A616-B6473C9E1BF8Q35563726-3B2F5CDD-C91A-4C90-9A0D-295A49E1B7E2Q35683564-9976B693-AE79-42D9-A5A8-EA50B9B5D2E7Q35754831-2AF56E0E-4B26-4677-8BE4-0FEBCD35C8BCQ35875911-48496632-91FF-4918-8F8D-0C07D535A175Q35974781-62024203-4620-4C5B-AD93-ABF2083A22F3Q35976998-892D1AB2-D8F7-46EB-9CC6-4FF5EF9E392CQ36012682-D4A8A22C-ABDC-4F72-9302-E760CC6B63F6Q36144913-B202774D-DDA9-4E7B-B25D-6294A072EA14Q36249272-B985EA3A-21B0-4A76-B890-22EFB51E8645Q36286672-39769616-05A8-4D4D-92E0-A991A21455E5Q36310036-0C649C28-96ED-4CC8-AE94-076BEA30978AQ36669986-E4D9C93B-B657-4AB5-B144-E53C5AB3C99BQ36675328-DF4D9293-2EC0-4C75-AE6D-D20BE3D6F598Q37645061-7C80905F-2C6E-46D2-85BC-DCF65D670DEDQ37733938-9B6BDF72-9F03-4D38-A191-F139DAA9AB81Q38258619-309C47CB-87BB-4058-867A-2D7F5BA1E981Q38777346-3773F27E-ADAD-4287-897B-FC2528596B56Q39672306-0D4DD32F-A954-4B8B-9742-36EDE10694CAQ50059665-04EDDBB8-77C1-48B8-8E84-76414AD74462Q50117674-29D8A4F0-DBED-462C-BEBC-44C49669A002Q52430722-85126C2A-608C-414B-88F1-55C6862B5717Q52430732-C2B97077-6622-4433-9B20-CBA5E3D00E03Q55364585-FE2B3C62-6A29-4258-A9D7-2F4CF1F3409CQ57059036-8C48094E-7A1B-49B1-93DF-3D1C37A3C07CQ57634834-194620EE-6C5C-4C64-94DD-560F86CD8633Q73563833-12C6DBE9-0291-4B3B-A3B4-08CABF45F798Q79290471-5C47D0B2-E77C-4E52-984A-A4357B4633FCQ90535138-1ABA8CFB-8E03-4693-8E54-1600D9C469C3Q90748016-F48131D0-1F2E-431B-A2D5-9A68F1B69670
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3881-7396
@en
name
Pilar Blancafort
@ast
Pilar Blancafort
@en
Pilar Blancafort
@es
Pilar Blancafort
@nl
type
label
Pilar Blancafort
@ast
Pilar Blancafort
@en
Pilar Blancafort
@es
Pilar Blancafort
@nl
prefLabel
Pilar Blancafort
@ast
Pilar Blancafort
@en
Pilar Blancafort
@es
Pilar Blancafort
@nl
P106
P1153
8664576500
P21
P31
P496
0000-0002-3881-7396